We have located links that may give you full text access.
Prospective study on a novel treatment for leaking cystic bleb: efficacy and safety of collagen crosslinking.
Clinical & Experimental Ophthalmology 2019 April 25
IMPORTANCE: Management of cystic bleb leak is difficult. It would be essential to look for a method to strengthen the original pathological conjunctiva and reverse bleb leak.
BACKGROUND: To evaluate the long-term efficacy and safety of collagen crosslinking in patients with leaking cystic bleb.
DESIGN: Prospective interventional case series at a university-based hospital.
PARTICIPANTS: Twelve eyes in 12 subjects with late onset bleb leak from cystic bleb, without indications for prompt surgical interventions were included.
METHODS: The subjects underwent crosslinking with 0.1% riboflavin application to bleb surface, followed by ultraviolet irradiation for 30 minutes. The subjects were followed up at baseline and at 1 week, 1 month, 3months, 6 months post treatment, and then every 6 months afterwards.
MAIN OUTCOME MEASURES: Interval from treatment to cessation of bleb leak, recurrence rate of bleb leak, and side effects of treatment.
RESULTS: The mean follow-up after crosslinking was 29.33±12.45 months. Bleb leak subsided in 11/12 (92%) patients after a single session of crosslinking, after 1 to 8 weeks (median 3 weeks). Time to leak cessation was significantly correlated with the number of prior glaucoma interventions (R=0.71,P=0.014). Bleb wall at 3 months was significantly thicker than at baseline (0.70±0.67 vs. 0.81±0.62 mm, P=0.008). None of the patients experienced any complications.
CONCLUSIONS AND RELEVANCE: Crosslinking achieves resolution of cystic bleb leak which lasts for at least 12 months, without the need of subsequent surgical interventions. Crosslinking is a simple, non-invasive treatment for bleb leak. It aims to restore the integrity of conjunctiva. This article is protected by copyright. All rights reserved.
BACKGROUND: To evaluate the long-term efficacy and safety of collagen crosslinking in patients with leaking cystic bleb.
DESIGN: Prospective interventional case series at a university-based hospital.
PARTICIPANTS: Twelve eyes in 12 subjects with late onset bleb leak from cystic bleb, without indications for prompt surgical interventions were included.
METHODS: The subjects underwent crosslinking with 0.1% riboflavin application to bleb surface, followed by ultraviolet irradiation for 30 minutes. The subjects were followed up at baseline and at 1 week, 1 month, 3months, 6 months post treatment, and then every 6 months afterwards.
MAIN OUTCOME MEASURES: Interval from treatment to cessation of bleb leak, recurrence rate of bleb leak, and side effects of treatment.
RESULTS: The mean follow-up after crosslinking was 29.33±12.45 months. Bleb leak subsided in 11/12 (92%) patients after a single session of crosslinking, after 1 to 8 weeks (median 3 weeks). Time to leak cessation was significantly correlated with the number of prior glaucoma interventions (R=0.71,P=0.014). Bleb wall at 3 months was significantly thicker than at baseline (0.70±0.67 vs. 0.81±0.62 mm, P=0.008). None of the patients experienced any complications.
CONCLUSIONS AND RELEVANCE: Crosslinking achieves resolution of cystic bleb leak which lasts for at least 12 months, without the need of subsequent surgical interventions. Crosslinking is a simple, non-invasive treatment for bleb leak. It aims to restore the integrity of conjunctiva. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app